Second Side Agreement - ACLARA BioSciences Inc. and PE Corp.
SECOND SIDE AGREEMENT
This Second Side Agreement ("Second Side Agreement"), retroactively effective as
of the 30th day of September, 2000 ("Second Side Agreement Effective Date"), is
by and between ACLARA BIOSCIENCES, INC., located at 1288 Pear Avenue, Mountain
View, California, 94043 ("Aclara") and PE CORPORATION (NY), having its Applied
Biosytems Group located at 850 Lincoln Center Drive, Foster City, California
94404 ("ABG"). Aclara and ABG will be referred to collectively as the "Parties."
BACKGROUND
A. Prior to this Second Side Agreement, Aclara and ABG have entered into
five agreements relating to the development and commercialization of
microfluidic technology in the field of High Throughput Screening:
1. a Collaboration Agreement having an effective date of April 25, 1998
(the "GA Agreement");
2. a Custom Instrument Development And Commercialization Agreement
having an effective date of October 1, 1998 (the "PRI
Agreement");
3. a Collaboration Agreement having an effective date of March 19, 1999
(the "HTS Agreement");
4. a Side Agreement having an effective date of March 19, 1999 (the
"PRI Side Agreement"); and
5. an Amendment To Collaboration Agreement having an effective date of
March 20, 2001 (the "Caliper Amendment").
B. The Parties wish to modify their contractual relations in the field of
High Throughput Screening in order to facilitate Aclara's independent
development of certain instrument systems and microfluidic devices.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual
promises and covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, do hereby agree as follows:
1
<PAGE>
AGREEMENT
1. NEW DEFINITIONS
1.1 DEFINITIONS. Any words with initial capitalization that are used in
this Second Side Agreement that are not otherwise defined in this
Second Side Agreement will have the meanings set forth in the HTS
Agreement.
1.2 "Affiliates" has the meaning set forth at Section 1.1 of the HTS
Agreement.
1.3 "Collaboration ACLARA Intellectual Property" has the meaning set forth
at Section 1.4 of the HTS Agreement.
1.4 "Collaboration Field" has the meaning set forth at Section 1.20 of the
HTS Agreement.
1.5 "Collaboration PERKIN-ELMER Intellectual Property" has the meaning set
forth at Section 1.6 of the HTS Agreement.
1.6 "Exclusive Period" has the meaning set forth at Section 1.8 of the HTS
Agreement.
1.7 "Existing Agreements" means the GA Agreement, the HTS Agreement, the
PRI Agreement, the PRI Side Agreement, and the Caliper Amendment.
1.8 "High Throughput Screening" has the meaning set forth at Section 1.17
of the HTS Agreement.
1.9 "Microfluidic Electrophoresis Device" has the meaning set forth at
Section 1.21 of the HTS Agreement.
1.10 "Post Exclusive Period Product" means any Collaboration Product that is
developed by Aclara or Aclara's Affiliate or licensee independently
from ABG after the expiration of the Exclusive Period.
1.11 "Pre-Collaboration ACLARA Intellectual Property" has the meaning set
forth at Section 1.3 of the HTS Agreement.
1.12 "PRI" means The R.W. Johnson Pharmaceutical Research Institute, a
Division of Ortho-McNeil Pharmaceutical, Inc.
1.13 "Subject Patents" has the meaning set forth at Section 1.13 of the HTS
Agreement.
2
<PAGE>
2. ACCELERATION OF THE EXCLUSIVE PERIOD
The Parties agree to alter the term of the Exclusive Period such that the
Exclusive Period will end upon the Second Side Agreement Effective Date. As
such, existing Section 1.8 of the HTS Agreement is hereby deleted and replaced
by the following:
1.8 "Exclusive Period" means the term beginning on the Effective
Date and ending upon the Second Side Agreement Effective Date.
3. REALLOCATION OF RESPONSIBILITIES
Certain responsibilities of the Parties with respect to the commercialization of
Post Exclusive Period Product are hereby clarified or altered from those set
forth in the HTS Agreement as follows:
(A) for the sake of clarity, the Parties agree that the development and
commercialization of the Post Exclusive Period Product will be excluded
from the exclusivity provisions of Sections 3.2.1 and 3.3.1 of the HTS
Agreement;
(B) ABG grants to Aclara and its Affiliates a non-exclusive license, with
the right to license third parties through the sale of Post Exclusive
Period Product or for the purpose of manufacture of Post Exclusive
Period Product, under Valid Claims of Subject Patents which claim
Collaboration PERKIN-ELMER Intellectual Property as reasonably
necessary to effect the use, development and commercialization of the
Post Exclusive Period Product by Aclara and its Affiliates or
licensees, as such non-exclusive license is set forth at Section 5.4.5
of the HTS Agreement, provided, however, any royalties shall be due
only with respect to Post Exclusive Period Product that is covered by a
Valid Claim of a Subject Patent which claims Collaboration PERKIN-ELMER
Intellectual Property;
(C) ABG grants to Aclara and its Affiliates a non-exclusive, royalty-free
license, with the right to license third parties, under Valid Claims of
Subject Patents which claim Collaboration Joint Intellectual Property
as necessary or useful to effect the use, development and
commercialization of the Post Exclusive Period Product by Aclara and
its Affiliates or licensees;
(D) for the sake of clarity, nothing in this Second Side Agreement will
restrict the rights of Aclara nor require Aclara to pay royalties with
respect to claims of Subject Patents which claim Pre-Collaboration
ACLARA Intellectual Property or Collaboration ACLARA Intellectual
Property;
(E) for the sake of clarity, the Parties agree that notwithstanding Section
3.2.2 of the HTS Agreement, Aclara will be responsible for all expenses
relating to the marketing, sales, and support of the Post Exclusive
Period Product; and
3
<PAGE>
(F) notwithstanding Section 3.2.3 of the HTS Agreement, the Post Exclusive
Period Product developed by Aclara will be marked so as to indicate
that such product is a product of Aclara and/or its Affiliate or
licensee alone, and not a product of ABG.
4. PRI AGREEMENT
4.1 PAYMENTS FROM PRI. The Parties agree that any and all future payments
by PRI under the PRI Agreement (including, without limitation, all
payments that were accrued under Article 6 of the HTS agreement prior
to or after the Second Side Agreement Effective Date but have not yet
been paid by PRI) may, in Aclara's discretion, be made by PRI directly
and solely to Aclara.
4.2 RIGHTS AND OBLIGATIONS. The Parties agree that, concurrently with this
Second Side Agreement, the PRI Agreement will be separately amended in
writing by the Parties and PRI such that (A) as an express condition to
ABG's obligations under this Article 4, PRI shall grant to ABG a
release in writing of all future obligations to PRI under the PRI
Agreement except for ABG's confidentiality obligations thereunder and
all such released obligations will be assumed solely by ACLARA, and (B)
the PRI Agreement shall be amended with respect to ABG as of the Second
Side Agreement Effective Date and all future rights of ABG under the
PRI Agreement will accrue solely to Aclara.
5. NO LICENSES
No license other than the licenses expressly set forth at Section 3(B) and 3(C)
of this Second Side Agreement is granted hereunder, whether express, implied, or
by estoppel, to any patent rights, or any other intellectual property rights,
owned, used, licensed to, or otherwise controlled by, ABG.
6. CONTINUED FORCE AND EFFECT OF EXISTING AGREEMENTS
All provisions of the Existing Agreements, except as modified by this Second
Side Agreement, will remain in full force and effect and are hereby reaffirmed.
Other than as expressly stated in this Second Side Agreement, this Second Side
Agreement will not operate as a waiver of any condition or obligation imposed on
the Parties under the Existing Agreements.
4
<PAGE>
7. INTERPRETATION OF SECOND SIDE AGREEMENT
In the event of any conflict, inconsistency, or incongruity between any
provision of this Second Side Agreement and any provision of the Existing
Agreements, the provisions of this Second Side Agreement will govern and
control.
8. ASSIGNABILITY
This Second Side Agreement and the licenses herein granted will be binding upon
and inure to the benefit of the successors in interest of the respective
Parties. Neither Party has the power to assign this Agreement nor any interest
hereunder without the written consent of the other Party; provided, however,
that either Party may assign this Agreement or any of its rights or obligations
to any Affiliate or to any third party with which it may merge or consolidate,
or to which it may transfer all or substantially all of its assets to which this
Agreement relates, without obtaining the consent of the other Party, subject to
such Affiliate or third party assuming all liabilities and obligations under
this Second Side Agreement.
9. ENTIRE AGREEMENT
This Second Side Agreement, along with the Existing Agreements, constitute the
sole agreements between the Parties relating to the subject matter hereof and
supersede all previous writings and understandings. Neither Party has been
induced to enter into this Second Side Agreement by, nor is any Party relying
on, any representation or warranty outside those expressly set forth in this
Second Side Agreement.
10. COUNTERPARTS
This Second Side Agreement may be executed in any number of counterparts, and
each counterpart will be deemed an original instrument, but all counterparts
together will constitute one agreement.
[Signature page follows.]
5
<PAGE>
The Parties, through their authorized officers, have executed this Second Side
Agreement as of the Second Side Agreement Effective Date.
ACLARA BIOSCIENCES, INC. PE CORPORATION (NY), THROUGH
ITS APPLIED BIOSYSTEMS GROUP
By: /s/ Joseph M. Limber By: /s/ Michael W. Hunkapiller
Name: Joseph M. Limber Name: Michael W. Hunkapiller
Title: President and Chief Executive Title: President Applied Biosystems
Group, Executive Vice President,
PE Corporation (NY)
Date: October 15, 2001 Date: October 8, 2001
------------------------------ ------------------------------
6